NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

Benedetti, D, Tissino, E, Caldana, C, Dal Bo, M, Bomben, R, Marconi, D, Ganghammer, S, Zaja, F, Pozzato, G, Di Raimondo, F, Hartmann, TN, Del Poeta, G, VanMeter, A, Zucchetto, A, Espina, V, Liotta, L, Gattei, V. Leukemia. 2016, 30(2): 513-517.

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer, F, Dejaco, M, Grabmer, C, Melchardt, T, Neureiter, D, Mayer, G, Egle, A, Greil, R, Weiss, L. Wien Klin Wochenschr. 2016.

Interessante PraМ€sentationen am europaМ€ischen Krebskongress: Neue Daten beim Mammakarzinom.

Gampenrieder, SP. Spectrum Onkologie. 2015. 05: 34-36.

Ropeginterferon alfa-2b, a novel IFNО±-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Gisslinger, H, Zagrijtschuk, O, Buxhofer-Ausch, V, Thaler, J, Schloegl, E, Gastl, GA, Wolf, D, Kralovics, R, Gisslinger, B, Strecker, K, Egle, A, Melchardt, T, Burgstaller, S, Willenbacher, E, Schalling, M, Them, NC, Kadlecova, P, Klade, C, Greil, R. Blood. 2015, 126(15): 1762-1769.

Response to comment by P. Vassilakopoulos and colleagues.

Jaeger, U, Praxmarer, M, Greil, R. Haematologica. 2015, 100(11): e482.

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer, F, Melchardt, T, Tränkenschuh, W, Neureiter, D, Moser, G, Magnes, T, Weiss, L, Schlattau, A, Hufnagl, C, Ricken, G, Höftberger, R, Greil, R, Egle, A. BMC Cancer. 2015, 15:996.

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

Melchardt, T, Troppan, K, Weiss, L, Hufnagl, C, Neureiter, D, Tränkenschuh, W, Schlick, K, Huemer, F, Deutsch, A, Neumeister, P, Greil, R, Pichler, M, Egle, A. J Natl Compr Canc Netw. 2015, 13(12):1501-1508.

Cytomegalovirus reactivation and its clinical impact in patients with solid tumors.

Schlick, K, Grundbichler, M, Auberger, J, Kern, JM, Hell, M, Hohla, F, Hopfinger, G, Greil, R. INFECT AGENTS CANCER. 2015, 10:.

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt, T, Hufnagl, C, Magnes, T, Weiss, L, Hutarew, G, Neureiter, D, Schlattau, A, Moser, G, Gaggl, A, Tränkenschuh, W, Greil, R, Egle, A. BMC Cancer. 2015, 15:725.

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer, S, Hutterer, E, Hinterseer, E, Brachtl, G, Asslaber, D, Krenn, PW, Girbl, T, Berghammer, P, Geisberger, R, Egle, A, Zucchetto, A, Kruschinski, A, Gattei, V, Chigaev, A, Greil, R, Hartmann, TN. Oncotarget. 2015, 6(14): 12048-12060.